Your browser doesn't support javascript.
loading
Lipoprotein(a), Oxidized Phospholipids, and Coronary Artery Disease Severity and Outcomes.
Gilliland, Thomas C; Liu, Yuxi; Mohebi, Reza; Miksenas, Hannah; Haidermota, Sara; Wong, Megan; Hu, Xingdi; Cristino, Joaquim Rosado; Browne, Auris; Plutzky, Jorge; Tsimikas, Sotirios; Januzzi, James L; Natarajan, Pradeep.
Afiliação
  • Gilliland TC; Division of Cardiology, Massachusetts General Hospital, Boston, Massachusetts, USA; Program in Medical and Population Genetics and the Cardiovascular Disease Initiative, Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA; Department of Medicine, Harvard Medical School, Boston, Massach
  • Liu Y; Division of Cardiology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Mohebi R; Division of Cardiology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Miksenas H; Division of Cardiology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Haidermota S; Division of Cardiology, Massachusetts General Hospital, Boston, Massachusetts, USA; Program in Medical and Population Genetics and the Cardiovascular Disease Initiative, Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA.
  • Wong M; Division of Cardiology, Massachusetts General Hospital, Boston, Massachusetts, USA; Program in Medical and Population Genetics and the Cardiovascular Disease Initiative, Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA.
  • Hu X; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
  • Cristino JR; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
  • Browne A; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
  • Plutzky J; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA; Division of Cardiology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Tsimikas S; Sulpizio Cardiovascular Center, University of California San Diego, La Jolla, California, USA.
  • Januzzi JL; Division of Cardiology, Massachusetts General Hospital, Boston, Massachusetts, USA; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA; Baim Institute for Clinical Research, Boston, Massachusetts, USA.
  • Natarajan P; Division of Cardiology, Massachusetts General Hospital, Boston, Massachusetts, USA; Program in Medical and Population Genetics and the Cardiovascular Disease Initiative, Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA; Department of Medicine, Harvard Medical School, Boston, Massach
J Am Coll Cardiol ; 81(18): 1780-1792, 2023 05 09.
Article em En | MEDLINE | ID: mdl-37137588
ABSTRACT

BACKGROUND:

Lipoprotein(a) (Lp[a]) and oxidized phospholipids (OxPLs) are each independent risk factors for atherosclerotic cardiovascular disease. The extent to which Lp(a) and OxPLs predict coronary artery disease (CAD) severity and outcomes in a contemporary, statin-treated cohort is not well established.

OBJECTIVES:

This study sought to evaluate the relationships between Lp(a) particle concentration and OxPLs associated with apolipoprotein B (OxPL-apoB) or apolipoprotein(a) (OxPL-apo[a]) with angiographic CAD and cardiovascular outcomes.

METHODS:

Among 1,098 participants referred for coronary angiography in the CASABLANCA (Catheter Sampled Blood Archive in Cardiovascular Diseases) study, Lp(a), OxPL-apoB, and OxPL-apo(a) were measured. Logistic regression estimated the risk of multivessel coronary stenoses by Lp(a)-related biomarker level. Cox proportional hazards regression estimated the risk of major adverse cardiovascular events (MACEs) (coronary revascularization, nonfatal myocardial infarction, nonfatal stroke, and cardiovascular death) in follow-up.

RESULTS:

Median Lp(a) was 26.45 nmol/L (IQR 11.39-89.49 nmol/L). Lp(a), OxPL-apoB, and OxPL-apo(a) were highly correlated (Spearman R ≥0.91 for all pairwise combinations). Lp(a) and OxPL-apoB were associated with multivessel CAD. Odds of multivessel CAD per doubling of Lp(a), OxPL-apoB, and OxPL-apo(a) were 1.10 (95% CI 1.03-1.18; P = 0.006), 1.18 (95% CI 1.03-1.34; P = 0.01), and 1.07 (95% CI 0.99-1.16; P = 0.07), respectively. All biomarkers were associated with cardiovascular events. HRs for MACE per doubling of Lp(a), OxPL-apoB, and OxPL-apo(a) were 1.08 (95% CI 1.03-1.14; P = 0.001), 1.15 (95% CI 1.05-1.26; P = 0.004), and 1.07 (95% CI 1.01-1.14; P = 0.02), respectively.

CONCLUSIONS:

In patients undergoing coronary angiography, Lp(a) and OxPL-apoB are associated with multivessel CAD. Lp(a), OxPL-apoB, and OxPL-apo(a) are associated with incident cardiovascular events. (Catheter Sampled Blood Archive in Cardiovascular Diseases [CASABLANCA]; NCT00842868).
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença da Artéria Coronariana / Doenças Cardiovasculares Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: J Am Coll Cardiol Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença da Artéria Coronariana / Doenças Cardiovasculares Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: J Am Coll Cardiol Ano de publicação: 2023 Tipo de documento: Article